|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.00 CNY | -0.27% |
|
-0.95% | -0.51% |
| 09-13 | China Accepts Hengrui Medicine Unit's Marketing Application for Cancer Drug | MT |
| 09-05 | Hengrui Medicine Gets China Nod for Anti-Hair Loss Drug | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Enjoy this offer
* See conditions on site
| Capitalization | 286B 40.49B 3,048B | P/E ratio 2024 * |
47.4x | P/E ratio 2025 * | 43.3x |
|---|---|---|---|---|---|
| Enterprise value | 267B 37.76B 2,843B | EV / Sales 2024 * |
9.74x | EV / Sales 2025 * | 8.63x |
| Free-Float |
52.34% | Yield 2024 * |
0.5% | Yield 2025 * | 0.53% |
More valuation ratios
* Estimated data
More news
More recommendations
More press releases
| 1 day | -0.27% | ||
| 1 week | -0.95% | ||
| Current month | +1.97% | ||
| 1 month | +4.36% | ||
| 3 months | +7.22% | ||
| 6 months | -4.82% | ||
| Current year | -0.51% |
1 week
44.40
45.59
1 month
41.8045.78
Current year
35.5149.15
1 year
35.5149.74
3 years
27.0055.54
5 years
27.0097.39
10 years
8.3797.39
| Director | Title | Age | Since |
|---|---|---|---|
Hong Bin Dai
CEO | Chief Executive Officer | 48 | 30/06/00 |
Jian Jun Liu
DFI | Director of Finance/CFO | 47 | 18/11/21 |
Yu Xu
CMP | Compliance Officer | 32 | 31/05/21 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jie Ping Sun
BRD | Director/Board Member | 54 | 31/12/97 |
Hong Bin Dai
CEO | Chief Executive Officer | 48 | 30/06/00 |
Piao Yang Sun
CHM | Chairman | 65 | 28/02/03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.18% | 1 M€ | -20.08% | - | |
| 3.73% | 2 M€ | -14.14% | ||
| 1.74% | 1 M€ | -9.86% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.27% | -0.95% | +1.44% | -4.15% | 40.51B | ||
| +0.89% | -2.49% | +58.57% | +293.58% | 816B | ||
| +1.81% | -1.75% | +38.83% | +183.17% | 583B | ||
| -0.50% | +0.41% | +1.92% | +0.92% | 402B | ||
| +0.39% | -0.09% | +26.29% | +82.19% | 342B | ||
| -1.26% | +1.66% | +9.13% | +62.89% | 300B | ||
| -0.34% | +1.71% | +4.07% | -21.67% | 255B | ||
| +0.35% | -1.26% | +12.08% | +39.01% | 243B | ||
| +0.41% | 0.00% | +7.00% | +27.50% | 235B | ||
| +1.25% | +2.16% | +27.58% | +56.75% | 179B | ||
| Average | +0.30% | -0.36% | +18.69% | +72.02% | 339.47B | |
| Weighted average by Cap. | +0.50% | -0.58% | +27.55% | +121.96% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 27.03B 3.82B 288B | 29.79B 4.21B 317B |
| Net income | 6.04B 854M 64.32B | 6.65B 941M 70.82B |
| Net Debt | -22.81B -3.23B -243B | -28.91B -4.09B -308B |
More financial data
* Estimated data
Employees
19,611
Sector
Pharmaceuticals
Calendar
24/10/2024
- Q3 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/09/24 | 45.00 ¥ | -0.27% | 22,401,150 |
| 18/09/24 | 45.12 ¥ | +0.78% | 17,507,900 |
| 13/09/24 | 44.77 ¥ | -0.44% | 19,509,730 |
| 12/09/24 | 44.97 ¥ | -1.01% | 18,657,810 |
| 11/09/24 | 45.43 ¥ | +2.14% | 29,157,830 |
End-of-day quote Shanghai S.E., September 18, 2024
More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
45.00CNY
Average target price
58.20CNY
Spread / Average Target
+29.33%
- Stock Market
- Equities
- 600276 Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition